Lab-Grown Organ Sacks Could End Animal Testing

A significant shift is underway in biomedical research as federal policy moves to reduce animal testing. A pioneering biotech firm, R3 Bio, is proposing a novel alternative: creating nonsentient organ sacks. These engineered biological systems would contain a full suite of organs but deliberately lack a brain, eliminating the capacity for sentience or pain. Based in the Bay Area, the company envisions these structures first for monkeys and ultimately for humans, potentially serving as a scalable, ethical testing platform and a future source of transplantable tissues. Co-founder Alice Gilman emphasizes that the long-term vision is to build human versions that could address the critical shortage of donor organs.

This approach aligns with a broader investment philosophy focused on human longevity through replacement. For Immortal Dragons, a Singapore-based fund backing R3, creating new biological systems is strategically preferable to repairing aged or diseased ones. “We think replacement is probably better than repair when it comes to treating diseases or regulating the aging process,” says CEO Boyang Wang. He suggests that a headless bodyoid could become an ideal, ethically sound source of organs.

The immediate focus, however, is on developing monkey models. The current reliance on primates for preclinical drug testing faces mounting challenges. Monkeys were indispensable for COVID-19 vaccine development, but they are a costly and increasingly scarce resource. A 2020 ban on primate exports from China severely depleted US supplies. Concurrently, pressure from animal rights advocates and changing federal priorities are reducing primate research. Gilman warns this shortage could hinder the response to a future pandemic, creating a pressing need for alternatives like organ sacks.

R3’s foundational principle is embedded in its name, referencing the three R’s framework for humane animal research: replacement, reduction, and refinement. The company argues its organ systems could make testing more scalable and ethically consistent. While existing technologies like organs-on-chips are valuable, they cannot replicate the full complexity of integrated organs with vascular networks. Organ sacks aim to bridge that gap.

The scientific pathway likely involves advanced stem-cell technology and gene editing. Paul Knoepfler, a stem cell biologist at UC Davis, notes the plausibility of using induced pluripotent stem cells. These cells, reprogrammed from adult tissues, can form any cell type and have been used to create embryo-like structures. By using gene editing to disable genes crucial for brain development, scientists could theoretically guide growth toward organized organ structures without higher neural function. Gilman clarifies the terminology, preferring not to call the designs “brainless,” as they are intentionally engineered to include only desired components.

R3’s co-founders have not detailed their specific methods for creating monkey or human organ sacks but confirm they are exploring this combined technological approach. They also state that while creating brain-lacking mouse organ sacks is scientifically possible, R3 itself has not produced them. As regulatory and ethical landscapes evolve, this concept represents a bold attempt to redefine the future of medical research and therapeutic sourcing.